anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A hair tonic cosmetic that is obtained by adding a tartaric acid nicotinic alcohol ester, thus continuously accelerating scalp blood circulation to develop good effect of hair growth, depilation prevention and dandruff prevention. CONSTITUTION:The objective hair tonic cosmetic contains 0.1-0.3wt% tartaric acid nicotinic alcohol ester of the formula. The compound of the formula has high action to increase peripheral blood flow and is appropriately absorbed through skin so that its concentration can be kept at an effective concentration in scalp tissues. Further, skin irritation is reduced and it can activate the hair matrix to develop hair growth and depilation inhibition effects. Further, the scalp metabolism is normalized to increase dandruff prevention. The cosmettic can be combined with colorants, perfumes, fungicides, preservative, corneum solubilizer, antiandrogen and antioxidants and prepared into hair tonic lotion, solution, cream or such.
PROBLEM TO BE SOLVED: To obtain a safe and stabilized preventive and therapeutic agent for circulatory system diseases for example hyperlipemia or arteriosclerosis by using a specific derivative prepared by treating alginic acid or its salt with cell bodies of a specific microorganism as an active ingredient. SOLUTION: This preventive and therapeutic agent contains an alginic oligosaccharide or its salt of formula I [R is H, metal ion; R' is G, M, G-G, M-G, M-M, G-G-G, G-G-M, G-M-G (M is D-mannuronic acid of formula II; G is L-gluronic acid of formula III; the bonds between individual monosaccharides are α- or β-1,4-bonds)]. The compound of formula I is obtained by treating alginic acid or its salt with cell bodies of a microorganism in Alteromonas or their treated product. A microorganism in Alteromonas is, for example, Alteromonas sp. No.1786. The alginic oligosaccharide or its salt may be used singly or in any combination of them.
FIELD: hygiene.SUBSTANCE: present invention relates to compositions for oral care containing a zinc source, comprising zinc oxide and zinc citrate; a bivalent tin source comprising bivalent tin pyrophosphate; a fluoride ion source comprising sodium fluoride; and an organic buffer, as well as to methods of using and producing such compositions. Described is an oral care composition containing: a zinc source, comprising zinc oxide and zinc citrate, where zinc citrate is present in amount of 0.25 to 1 wt. %, and zinc oxide is present in amount of 0.75 to 1.25 wt. % in terms of total weight of composition; a bivalent tin source comprising bivalent tin pyrophosphate, where bivalent tin pyrophosphate is present in amount of 0.1 wt. % to 2 wt. % in terms of total weight of composition; a fluoride ion source comprising sodium fluoride; and an organic acid-based buffer, where the organic acid-based buffer is a citrate buffer, wherein the citric acid is in amount of 0.6 wt. %, and trisodium citrate is present in amount of 1.5 wt. %.EFFECT: technical result is creation of compositions for oral care, providing the advantages of stable protection against microorganisms without significant negative effect on stability of the composition with antibacterial efficacy, which are also pleasant to taste and claimed by consumer.12 cl, 2 tbl, 2 ex
Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \> 100-500/uL following the nadir or the next chemotherapy course begins.
The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
Beginning cycle 0, patients receive lenvatinib PO QD on days 1-21. Beginning cycle 1, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
The invention provides an MSMP secretory protein with leucocyte chemotactic activity and with amino acid sequence represented by SEQ ID NO: 1, a polynucleotide coding the protein, and a genetic engineering vector comprising the polynucleotide. The invention also relates to a medicine composition comprising the protein or polynucleotide, the genetic engineering vector and/or a host cell, and pharmaceutically acceptable salt, carrier, or excipient. The invention also relates to an in-vitro detection method of expression level changes of the protein or polynucleotide. The protein or polynucleotide can be used in preventing and/or treating viral infections, allergic diseases, inflammation responses, transplant rejection, autoimmune diseases, tumors, tumor metastasis, immunomodulatory and stem cell proliferation and differentiation, osteoporosis, obesity and insulin resistance, atherosclerosis, and cardiovascular diseases such as vascular calcification. The protein or polynucleotide can also be used in commercial reagents used for researching the diseases. The invention also relates to the protein or polynucleotide as targets in developing compounds, antibodies, peptide medicines and commercial reagents.
A method, apparatus and computer program product are provided to update surgeon preference cards or similar records. In this regard, one or more instances may be identified in which the quantity of an item utilized during the medical procedure differed from the predefined quantity of the item supplied in preparation for the medical procedure. For example, the quantity of the item that was utilized most frequently during the medical procedure may be compared to the predefined quantity of the item. An adjustment to the predefined quantity of the item may then be determined if the quantity of the item that was actually utilized most frequently differed from the predefined quantity of the item. A recommendation can then be provided that the predefined quantity of the item be altered in accordance with the adjustment. Based on user response, the predefined quantity of the item may be altered.
Multiple novel multi-port robotic surgical systems have been introduced into clinical practice. This systematic review aims to evaluate the clinical outcomes of these novel robotic systems to conventional laparoscopic technique and established da Vinci robotic surgical platforms. A literature search of Embase, Medline, Pubmed, Cochrane library, and Google Scholar was performed according to the PRISMA guidelines from 2012 to May 2023. Studies comparing clinical outcomes of novel multi-port robotic surgical systems with laparoscopic or the da Vinci platforms were included. Case series with no comparison groups were excluded. Descriptive statistics were used to report patient and outcome data. A systematic narrative review was provided for each outcome. Twelve studies comprised of 1142 patients were included. A total of 6 novel multi-port robotic systems: Micro Hand S, Senhance, Revo-i MSR-5000, KangDuo, Versius, and Hugo™ RAS were compared against the laparoscopic or the da Vinci robotic platforms. Clinical outcomes of these novel robotic platforms were comparable to the established da Vinci platforms. When compared against conventional laparoscopic approaches, the robotic platforms demonstrated lower volume of blood loss, shorter length of stay but longer operative time. This systematic review highlighted the safe implementation and efficacy of 6 new robotic systems. The clinical outcomes achieved by these new robotic systems are comparable to the established da Vinci robotic system in simple to moderate case complexities. There is emerging evidence that these new robotic systems provide a viable alternative to currently available robotic platforms.
The efficacy of Cymbalta for the management of neuropathic pain associated with diabetic peripheral neuropathy was established in 2 randomized, 12-week, double-blind, placebo-controlled, fixed-dose studies in adult patients having diabetic peripheral neuropathic pain for at least 6 months. Study 1 and 2 enrolled a total of 791 patients of whom 592 (75%) completed the studies. Patients enrolled had Type I or II diabetes mellitus with a diagnosis of painful distal symmetrical sensorimotor polyneuropathy for at least 6 months. The patients had a baseline pain score of ≥4 on an 11-point scale ranging from 0 (no pain) to 10 (worst possible pain). Patients were permitted up to 4 g of acetaminophen per day as needed for pain, in addition to Cymbalta. Patients recorded their pain daily in a diary.

Both studies compared Cymbalta 60 mg once daily or 60 mg twice daily with placebo. Study 1 additionally compared Cymbalta 20 mg with placebo. A total of 457 patients (342 Cymbalta, 115 placebo) were enrolled in Study 1 and a total of 334 patients (226 Cymbalta, 108 placebo) were enrolled in Study 2. Treatment with Cymbalta 60 mg one or two times a day statistically significantly improved the endpoint mean pain scores from baseline and increased the proportion of patients with at least a 50% reduction in pain score from baseline. For various degrees of improvement in pain from baseline to study endpoint, Figures 1 and 2 show the fraction of patients achieving that degree of improvement. The figures are cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in pain as early as week 1, which persisted throughout the study.

Figure 1: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - Study 1

Figure 2: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - Study 2
The present invention relates to a compound smilax granule which has the efficiency of clearing away heat and toxic materials, softening and resolving hard mass and enriching yin and benefiting qi. The compound smilax granule is a Chinese material preparation for treating lung cancer and cervical cancer. The compound smilax granule has the following main components and weight percentage: 10 to 25% of smilax, 10 to 25% of heartleaf houttuynia herb, 10 to 25% of catclaw buttercup root, 10 to 25% of barbary wolfberry fruit, 10 to 25% of Chinese date (enucleation), 2 to 15% of ground beeltle, 2 to 15% of common coltsfoot flower, 5 to 20% of fresh snakehead and an amount of auxiliary materials. The present invention has the following preparation method: after the fresh snakehead is cut into sections, the fresh snakehead and the rest of seven medicines are filled with water and are decocted for two times; the first time is that 8 times of water is filled and is decocted for 1.5 hours; the second time is that 6 times of water is filled and is decocted for 1 hour; the decoction liquid is merged and filtered; then, the filter liquid is condensed into extract with 1.38 to 1.40 (60 to 65 DEG C heat measurement) of relative density; an amount of auxiliary materials are added into the extract and are uniformly blended to be made into granules, and after drying, granulation and separate loading, the compound smilax granule is obtained. The compound smilax granule is prepared from medicine, excipients, etc. After being dissolved into hot water, the compound smilax granule is administered, and accordingly, the present invention is convenient to be absorbed and is favorable to have the treating effects of the medicine.
The present invention relates to a cosmetic composition that prevents water-soluble ingredients from being destroyed due to external factors by coating water-soluble cosmetic ingredients by means of a cryoprotectant and to a method for producing same. Provided is a method for producing an s/o-type emersion powder cosmetic composition containing water-soluble ingredients, the method comprising the steps of: producing an aqueous phase by dissolving an s/o-type emersion powder cosmetic composition and water-soluble cosmetic components in water, wherein the s/o-type emersion powder cosmetic composition contains water-soluble components that are obtained by coating sterols on a water-soluble cosmetic ingredients and an emulsifier; producing an oil phase by adding an emulsifier to an organic solvent; producing w/o-type emulsion by mixing the aqueous phase and oil phase; and dissolving sterols in the emulsion in order to then be frozen and dried. The water-soluble ingredients in the cosmetic composition of the present invention are usually easily oxidized and destroyed due to external factors such as air, heat, light, and oxygen but are protected from the external factors by means of a coating film of a cryoprotectant so as to have improved qualities and content stability. Water is removed through a freezing and drying procedure so that the water-soluble ingredients can be prevented from being oxidized due to oxygen dissolved in the water and the composition of the present invention can be stored for a long period of time thereby. Moreover, the water-soluble ingredients are made into powder through the freezing and drying procedure so that the water-soluble components that are unstable in heat are prevented from losing titer during the production process thereof and the original activity thereof is maintained. The composition of the present invention is in powder form so that the composition can be mixed with the oil phase in order to be immediately changed into an emersion-type composition that maintains an aqueous phase and oil phase dispersed colloid state.
Signs and Symptoms — Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhea, and hematuria. If other symptoms are present, it is probably secondary to an underlying disease state, an allergic reaction, or toxicity due to ingestion of a second medication.

Treatment — To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

Unless 5 to 10 times the normal dose of cephalexin has been ingested, gastrointestinal decontamination should not be necessary.

Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying.

Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cephalexin; however, it would be extremely unlikely that one of these procedures would be indicated.

The oral median lethal dose of cephalexin in rats is >5000 mg/kg.
Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
Serious adverse reactions, including fatal reactions and the "gasping syndrome," have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions, because they may be less able to metabolize benzyl alcohol [see Use in Specific Populations (8.4)].

Use the preservative-free preparations of BLINCYTO where possible in neonates. When prescribing BLINCYTO (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway.

Monitor neonatal patients receiving BLINCYTO (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL [see Use in Specific Populations (8.4)].
This study will be conducted as a parallel group randomized controlled experimental study to determine the effect of listening to music in the uşşak makam on sleep quality in Behçet's Diseases.The population of the research will be Behçet's patients receiving outpatient treatment in the Rheumatology outpatient clinic of a university hospital.G.Power program was used to calculate the sample size of the study. In descriptive studies, the t tests - Means: Difference between two independent means (two groups) model was used to determine the sample size when the number of individuals in the universe was not known. While determining the sample volume in the research, the test for the main hypothesis was determined at the first stage and the required averages were obtained from Bakır's research in 2019, which is compatible with our study in the literature (Bakır, 2019). According to the g-power analysis, with 95% confidence level and α=0.05 margin of error, it has an effect size of 0.941 and a tolerance ratio of 5%; In this study, the power of the test was determined as p: 0.05, (1-β): 90%, t = 2.015, and in line with this information, it was concluded that the number of samples required for the study was 46 people in both groups. Considering the possible losses from the experimental study, the number of samples was increased by 10% and it was decided that the total sample size would be 50 people, 25 people in the intervention group and 25 people in the control group.Application In this study, intervention and control groups will be studied in a pre-test and post-test design. No intervention will be applied to the control group. Passive music listening practice for the intervention group.
The present invention provides methods and apparatus for coating surfaces with specially designed thioethers and amphiphilic thioethers that reduce protein adsorption and/or cell adhesion. This reduction may be achieved, for example, by controlling the spacing or length of pendant chains or hydrophilic blocks in an amphiphilic thioether. Techniques for determining spacing include adsorbing the thioether from a solution or a colloidal suspension, or controlling the degree of polymerization of the thioether. Techniques for controlling the length of the pendant chains include controlling the degree of polymerization of the pendant chains. Multiblock copolymers of poly(propylene sulfide) and poly(ethylene glycol) (“PPS-PEG”) represent an exemplary family of amphiphilic thioethers. Methods for coating surfaces with amphiphilic thioethers are also provided.
Before the study begins, the selected individuals will be identified by a numeric code and will receive instructions regarding oral hygiene as well as supragingival scaling in all teeth. According to a random numeric table generated by a computer software, the study coordinator will allocate each patient into one of the following groups: Control (Scaling and Root Planing - SRP) or Test (SRP + probiotic therapy). The subjects (Test and Control groups) will receive lozenge containing/not containing. In the Test group, the lozenge will present Bifidobacterium lactis HN019 (HN019). Individuals will be instructed (immediately after the first session of mechanical instrumentation) to consume twice a day for 4 weeks by dissolving the lozenge before bedtime, and when wake up. They will also be instructed not to consume other probiotic product during the study. Clinical, immunological and microbiological parameters will be assessed at baseline (pre-intervention) and after completion of non-surgical periodontal therapy 30 and 90 days. All patients will receive detailed information regarding the study (goals, benefits and risks) according to the Term of Consent. The sample size was determined using the software Graphpad Statemate 2.0 (GraphPad Software, Inc., San Diego, CA, USA). The ideal sample size to ensure an 80% power in the statistical analysis of the data obtained in this study was calculated considering the differences of means and standard deviations between the test and control groups of the study by Vivekananda et al. (2010). The α value was set at 0.05. The average dropout of patients in our previous studies (approximately 20%) was also considered to calculate the sample size. Thus, a sample size of at least 30 patients was considered appropriate for this study. The normality and homoscedasticity of the data obtained will be checked. Comparisons within groups and among groups at different time intervals will be performed through parametric or non-parametric appropriate tests. The significance level will be set at 5% in all tests. All calculations will be performed by SPSS software (SPSS, Chicago IL, USA).
BACKGROUND: Post-induction anaesthesia often promotes intraoperative hypotension (IOH) that can worsen postoperative outcomes. This study aims to assess the benefit of norepinephrine versus ephedrine at the induction of anaesthesia to prevent postoperative complications following major abdominal surgery by preventing IOH.
METHODS AND ANALYSIS: The EPON STUDY is a prospective single-centre randomised controlled trial with the planned inclusion of 500 patients scheduled for major abdominal surgery at the Amiens University Hospital. The inclusion criteria are patients aged over 50 years weighing more than 50 kg with an American Society of Anesthesiologists physical status score of ≥2 undergoing major abdominal surgery under general anaesthesia. Patients are allocated either to the intervention group (n=250) or the standard group (n=250). In the intervention group, the prevention of post-induction IOH is performed with norepinephrine (dilution to 0.016 mg/mL) using an electric syringe pump at a rate of 0.48 mg/h (30 mL/h) from the start of anaesthesia and then titrated to achieve the haemodynamic target. In the control group, the prevention of post-induction IOH is performed with manual titration of ephedrine, with a maximal dose of 30 mg, followed by perfusion with norepinephrine. In both groups, the haemodynamic target to maintain is a mean arterial pressure (MAP) of 65 mm Hg or 70 mm Hg for patients with a medical history of hypertension. An intention-to-treat analysis will be performed. The primary outcome is the Clavien-Dindo score assessed up to 30 days postoperatively. The secondary endpoints are the length of hospital stay and length of stay in an intensive care unit/postoperative care unit; postoperative renal function; postoperative cardiovascular, respiratory, neurological, haematological and infectious complications at 1 month; and volume of intraoperative vascular filling and mortality at 1 month.
ETHICS AND DISSEMINATION: Ethical approval was obtained from the committee of protection of the persons of Ile de France in May 2021 (number 21 05 41). The authors will be involved in disseminating the research findings (through attending conferences and co-authoring papers). The results of the study will be disseminated via peer-reviewed publications and presentations at national and international conferences.
TRIAL REGISTRATION NUMBER: NCT05276596.